Open AccessMulticenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgically resectable HNSCC after adjuvant therapy
Author(s) -
N Möckelmann,
Mascha Binder,
CS Betz,
ChiaJung Busch
Publication year - 2020
Publication title -
laryngo-, rhino-, otologie
Language(s) - English
Resource type - Conference proceedings
eISSN - 1438-8685
pISSN - 0935-8943
DOI - 10.1055/s-0040-1710984
Subject(s) - nivolumab , medicine , ipilimumab , immunotherapy , oncology , adjuvant , head and neck squamous cell carcinoma , radiation therapy , adjuvant therapy , head and neck cancer , cancer